Cormorant Asset Management, LP Design Therapeutics, Inc. Transaction History

Cormorant Asset Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$7.86 - $17.2 $1.18 Million - $2.58 Million	150,000 Added 3.0%	5,150,000 $52.8 Million
Q3 2022 Nov 14, 2022	SELL	$14.09 - $25.57 $7.05 Million - $12.8 Million	-500,000 Reduced 9.09%	5,000,000 $83.6 Million
Q2 2022 Aug 15, 2022	BUY	$9.91 - $17.33 $3.4 Million - $5.94 Million	343,006 Added 6.65%	5,500,000 $77 Million
Q1 2022 May 16, 2022	SELL	$11.17 - $20.89 $3.17 Million - $5.92 Million	-283,459 Reduced 5.21%	5,156,994 $83.3 Million
Q4 2021 Feb 14, 2022	BUY	$13.64 - $21.41 $1.03 Million - $1.62 Million	75,603 Added 1.41%	5,440,453 $116 Million
Q3 2021 Nov 15, 2021	SELL	$13.99 - $20.03 $699,500 - $1 Million	-50,000 Reduced 0.92%	5,364,850 $78.8 Million
Q2 2021 Aug 16, 2021	BUY	$19.02 - $29.78 $5.71 Million - $8.93 Million	300,000 Added 5.87%	5,414,850 $106 Million
Q1 2021 May 17, 2021	BUY	$29.52 - $41.49 $151 Million - $212 Million	5,114,850 New	5,114,850 $146 Million

102

31M

2.3K

16.5K

Ticker DSGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,807,900
Market Cap $347M
Description
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.